InsiderSignal.AI

InsiderSignal.ai

AUPH - Aurinia Pharmaceuticals Inc.

Insider Purchase by Tang Kevin (Dir)

1 Year
After Trade
Before Trade

Loading data...

Trade Summary

6 months ago, Tang Kevin, serving as Dir at Aurinia Pharmaceuticals Inc. (AUPH), purchased 1,300,000 shares at $10.45 per share, for a total transaction value of $13,590,000.00. Following this transaction, Tang Kevin now holds 11,329,500 shares of AUPH.

This purchase represents a 13.00% increase in Tang Kevin's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, August 1, 2025 and publicly disclosed via SEC Form 4 filing on Tuesday, August 5, 2025, 4 days after the trade was made.

Aurinia Pharmaceuticals Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Tang Kevin C

Tang Kevin

Dir

Kevin C. Tang (age 58) is the independent Chair of the Board at Aurinia Pharmaceuticals Inc. (AUPH) since September 12, 2024, also serving as Chair of the Governance & Nomination Committee and a member of the Audit and Compensation Committees.[[1]](https://fintool.com/app/research/companies/AUPH/people/kevin-tang)[[2]](https://www.auriniapharma.com/company/board-of-directors) Residing in California, he holds a B.S. from Duke University (1989) and founded Tang Capital Management, LLC in 2002, where he serves as President, focusing on life sciences investments.[[1]](https://fintool.com/app/research/companies/AUPH/people/kevin-tang)[[2]](https://www.auriniapharma.com/company/board-of-directors)[[4]](https://www.insidermonkey.com/hedge-fund/tang+capital+management/531/) Tang has a distinguished career in biotech, previously leading life sciences research as Managing Director at Deutsche Banc Alex Brown (1993–2001).[[1]](https://fintool.com/app/research/companies/AUPH/people/kevin-tang)[[2]](https://www.auriniapharma.com/company/board-of-directors) He co-founded and chaired companies like Heron Therapeutics (Director 2009–2012, Chairman 2012–2020), La Jolla Pharmaceutical (Chairman 2014–2022, acquired by Innoviva), Odonate Therapeutics (Founder, Chairman & CEO 2013–2022), Ardea Biosciences (Co-Founder, Director 2006–2012, acquired by AstraZeneca), and Penwest Pharmaceuticals (Director 2009–2010, acquired by Endo).[[1]](https://fintool.com/app/research/companies/AUPH/people/kevin-tang)[[2]](https://www.auriniapharma.com/company/board-of-directors)[[3]](https://www.marketscreener.com/insider/KEVIN-TANG-A03QAO/) He owns about 11.3 million AUPH shares (7.3% stake), waives director compensation, and maintains perfect board attendance.[[1]](https://fintool.com/app/research/companies/AUPH/people/kevin-tang)[[6]](https://www.gurufocus.com/insider/41771/kevin-c-tang)

View full insider profile →

Trade Price

$10.45

Quantity

1,300,000

Total Value

$13,590,000.00

Shares Owned

11,329,500

Trade Date

Friday, August 1, 2025

204 days ago

SEC Filing Date

Tuesday, August 5, 2025

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Aurinia Pharmaceuticals Inc.

Company Overview

No company information available
View news mentioning AUPH

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/106522

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime